Peptide Regulation Around the World: Legal Status in the US, EU, UK, and Australia

Peptides occupy an unusual regulatory space. They are not conventional small-molecule drugs, not biologics in the traditional sense, and not dietary supplements in most jurisdictions. The result is a patchwork of classification systems that varies significantly from country to country. This overview, maintained by the Peptide Register as part of its regulatory intelligence reference, summarises how peptides are classified in four major jurisdictions as of early 2026.

United States: FDA Oversight, Compounding, and the Category System

In the United States, most bioactive peptides with therapeutic intent are regulated as drugs by the Food and Drug Administration (FDA). The FDA regulates most therapeutic peptides as drugs, requiring Investigational New Drug (IND) applications before human clinical trials can proceed. Peptides that have completed the approval process, such as semaglutide and tesamorelin, are available by prescription only.

Compounding pharmacies have historically been a significant access point for peptides in the US. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare certain peptide formulations on a patient-specific or bulk basis. However, the FDA's Category 1, 2, and 3 classification system determines which bulk drug substances, including peptides, are eligible for compounding. The FDA placed several peptides including BPC-157 and AOD-9604 on its Category 2 list, restricting their use in compounding pending further safety review. This has narrowed the range of peptides available through compounded prescriptions. For more context on what this means globally, see the impact of the FDA Category 1 list on compounding.

Collagen peptides and certain amino acid chains sold as food or dietary supplements are regulated differently under the Dietary Supplement Health and Education Act (DSHEA), though the FDA has increasingly scrutinised products marketed with therapeutic claims. The distinction between supplement-grade peptides and research-grade bioactive peptides is important and often misunderstood; the Peptide Register's comparison of collagen peptides and bioactive signalling peptides explores this further.

European Union: Centralised and National Pathways

The European Medicines Agency (EMA) oversees peptide therapeutics at the EU level, with individual member states retaining authority over prescribing and compounding rules. The EMA classifies peptide therapeutics under the same regulatory framework as other medicinal products, requiring marketing authorisation before clinical use. Approved peptide drugs like octreotide and liraglutide are available across member states under standard prescription frameworks.

Compounding regulations in the EU vary by member state, with some countries permitting magistral (patient-specific) preparations. However, the EU does not have a harmonised compounding framework equivalent to the US 503A/503B system. Research-use peptides may be obtained through licensed chemical suppliers, but sale for human use without marketing authorisation is prohibited.

United Kingdom: MHRA and Post-Brexit Divergence

Since Brexit, the UK Medicines and Healthcare products Regulatory Agency (MHRA) operates independently of the EMA. The MHRA regulates peptide medicines under the Human Medicines Regulations 2012, and any peptide marketed for therapeutic use requires a marketing authorisation or special licence. The MHRA has taken enforcement action against unlicensed peptide products sold online within the UK.

UK compounding ("specials") is permitted under specific conditions, but prescribers must demonstrate clinical need, and the product must not have a licensed equivalent available. The UK does not maintain a public bulk drug substance list comparable to the FDA's category system.

Australia: TGA Scheduling and Prescription Requirements

Australia's Therapeutic Goods Administration (TGA) uses a scheduling system that classifies peptides by risk. The TGA classifies most bioactive peptides as Schedule 4 (prescription-only) substances in Australia. This means they require a prescription from a registered medical practitioner. Some peptides have been rescheduled in recent years; for a detailed breakdown, see the Peptide Register's guide to Schedule 4 classification and TGA scheduling changes in 2025.

Australia's compounding rules are governed by state pharmacy boards under the oversight of the TGA. Australian compounding pharmacies may prepare Schedule 4 peptides only with a valid prescription from an authorised prescriber. The TGA has also increased scrutiny of peptides imported through personal importation schemes, and enforcement against grey market peptide suppliers has intensified. The Peptide Register tracks these developments through its grey market monitoring section.

Key Differences and Common Threads

Despite jurisdictional differences, several patterns hold across all four regions. No major jurisdiction permits the sale of bioactive therapeutic peptides without medical oversight or regulatory authorisation. Grey market peptide sales operate outside regulatory frameworks in all four jurisdictions and carry significant quality and safety risks. The regulatory gap between peptide research activity and formal approval pathways continues to widen, as explored in the Peptide Register's analysis of clinical trials outpacing regulatory guidance.

Researchers and clinicians working with peptides should be aware that regulatory status can change rapidly, particularly in Australia and the US where scheduling and compounding eligibility are under active review. The Peptide Register maintains updated peptide profiles that include regulatory status by jurisdiction where available.